We also analyzed PD1 and PDL1 expression in MM and B-NHL primary BM or PB samples and demonstrated that one of these molecules is frequently expressed either on the tumor cells or on immune cells (T lymphocytes/monocytes/macrophages) in the tumor microenvironment, suggesting that BCMA×PDL1 may indeed be a useful therapeutic tool in both MM and B-NHL [33,34]. This evidence concerns the gene PDCD1 and Miyoshi myopathy.